Merck & Co., Inc. News
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
see moreMerck & Co., Inc. Market News
13d
Merck’s Animal Health Arm Gains FDA Nod for EXZOLT™ CATTLE‑CA1 Topical Parasiticide
- Merck’s animal health division secured U.S. conditional approval for EXZOLT™ CATTLE‑CA1, a new isoxazoline topical solution for cattle—marking a strategic product milestone.
27d
Merck Advances Canine Oncology with Gilvetmab Research Published This Week by Merck Animal Health
Merck Animal Health published landmark findings on gilvetmab, the first caninized immune checkpoint inhibitor for dogs, in top veterinary journals this week.
24 Sep at 05:24
Merck Scores EU CHMP Backing for KEYTRUDA + Padcev in Bladder Cancer Amid Solid Animal Health Momentum
Merck (MRK) receives positive CHMP opinion for KEYTRUDA plus Padcev in resectable muscle‑invasive bladder cancer, while its Animal Health segment drives steady growth.
10 Sep at 05:23
Moderna‑Merck Cancer Vaccine Trial Spurs MRK Rally to 52‑Week High
Merck shares surged after late‑stage melanoma mRNA vaccine results with Moderna drove stock to new 52‑week high amid oncology optimism.
27 Aug at 05:23
Merck Shares Rally on Breakthrough mRNA Melanoma Trial with Keytruda Partner
Merck (MRK) stock jumps after a late‑stage trial of an mRNA therapy plus Keytruda met efficacy targets in high‑risk melanoma, marking a major pharma milestone.